DONGIOVANNI, PAOLA
DONGIOVANNI, PAOLA
DIPARTIMENTO DI MEDICINA INTERNA (attivo dal 01/01/1998 al 27/04/2012)
Corrigendum to "SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease" [J Hepatol 80 (2024) 10-19]
2024 F. Salomone, R. Pipitone, M. Longo, F. Malvestiti, A. Amorini, A. Distefano, E. Casirati, E. Ciociola, N. Iraci, L. Leggio, R. Zito, N. Vicario, C. Saoca, V. Männistö, J. Pihlajamäki, S. Qadri, H. Yki-Järvinen, S. Romeo, G. Pennisi, D. Cabibi, G. Lazzarino, A. Fracanzani, P. Dongiovanni, L. Valenti, S. Petta, G. Volti, S. Grimaudo
Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH
2023 M.P. Moore, X. Wang, H. Shi, M. Meroni, A. Cherubini, L. Ronzoni, E.J. Parks, J.A. Ibdah, R.S. Rector, L. Valenti, P. Dongiovanni, I. Tabas
An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians
2023 A. Cespiati, F. Cinque, M. Meroni, R. Lombardi, P. Dongiovanni, A.L. Fracanzani
The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value
2023 E. Paolini, M. Longo, M. Meroni, G. Tria, A. Cespiati, R. Lombardi, S. Badiali, M. Maggioni, A.L. Fracanzani, P. Dongiovanni
Salivary biomarkers: novel noninvasive tools to diagnose chronic inflammation
2023 P. Dongiovanni, M. Meroni, S. Casati, R. Goldoni, D.V. Thomaz, N.S. Kehr, D. Galimberti, M. Del Fabbro, G.M. Tartaglia
Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease
2023 R.M. Pipitone, F. Malvestiti, G. Pennisi, O. Jamialahmadi, P. Dongiovanni, G. Bertolazzi, J. Pihlajamäki, H. Yki-Järvinen, U. Vespasiani-Gentilucci, F. Tavaglione, S. Maurotti, C. Bianco, G. Di Maria, M. Enea, A.L. Fracanzani, V. Kärjä, G. Lupo, V. Männistö, M. Meroni, R. Piciotti, S. Qadri, R. Zito, A. Craxì, V. Di Marco, C. Cammà, C. Tripodo, L. Valenti, S. Romeo, S. Petta, S. Grimaudo
Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis
2023 J. Kang, J. Postigo-Fernandez, K. Kim, C. Zhu, J. Yu, M. Meroni, B. Mayfield, A. Bartolomé, D.H. Dapito, A.W. Ferrante, P. Dongiovanni, L. Valenti, R.J. Creusot, U.B. Pajvani
Recent advances of drugs monitoring in oral fluid and comparison with blood
2023 S. Casati, M. Binda, P. Dongiovanni, M. Meroni, A. D'Amato, G. Roda, M. Orioli, M. DEL FABBRO, G.M. Tartaglia
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women
2023 A. Cherubini, M. Ostadreza, O. Jamialahmadi, S. Pelusi, E. Rrapaj, E. Casirati, G. Passignani, M. Norouziesfahani, E. Sinopoli, G. Baselli, C. Meda, P. Dongiovanni, D. Dondossola, N. Youngson, A. Tourna, S. Chokshi, E. Bugianesi, E. Study Investigators, S. DELLA TORRE, D. Prati, S. Romeo, L. Valenti
Quality-by-Design R&D of a Novel Nanozyme-Based Sensor for Saliva Antioxidant Capacity Evaluation
2023 R. Goldoni, D.V. Thomaz, L. Strambini, M. Tumedei, P. Dongiovanni, G. Isola, G. Tartaglia
Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
2022 A. Cespiati, M. Meroni, R. Lombardi, G. Oberti, P. Dongiovanni, A.L. Fracanzani
{PD}-1/{PD}-L1 Immuno-Mediated Therapy in {NAFLD}: Advantages and Obstacles in the Treatment of Advanced Disease
2022 R. Lombardi, R. Piciotti, P. Dongiovanni, M. Meroni, S.R. Fargion, A.L. Fracanzani
TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
2022 M. Longo, M. Meroni, E. Paolini, V. Erconi, F. Carli, F.R. Fortunato, D. Ronchi, R. Piciotti, S. Sabatini, C. Macchi, A. Alisi, L. Miele, G. Soardo, G.P. Comi, L.V.C. Valenti, M. Ruscica, A.L. Fracanzani, A. Gastaldelli, P. Dongiovanni
Rare ATG7 genetic variants predispose patients to severe fatty liver disease
2022 G.A. Baselli, O. Jamialahmadi, S. Pelusi, E. Ciociola, F. Malvestiti, M. Saracino, L. Santoro, A. Cherubini, P. Dongiovanni, M. Maggioni, C. Bianco, F. Tavaglione, A. Cespiati, R.M. Mancina, R. D'Ambrosio, V. Vaira, S. Petta, L. Miele, U. Vespasiani-Gentilucci, A. Federico, J. Pihlajamaki, E. Bugianesi, A.L. Fracanzani, H.L. Reeves, G. Soardo, D. Prati, S. Romeo, L.V. Valenti
Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
2022 M. Meroni, M. Longo, E. Paolini, G. Tria, M. Ripolone, L. Napoli, M. Moggio, A.L. Fracanzani, P. Dongiovanni
MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients
2022 M. Meroni, M. Longo, E. Paolini, R. Lombardi, R. Piciotti, P. Francione, S. Badiali, M. Maggioni, A.L. Fracanzani, P. Dongiovanni
Interaction between lifestyle changes and PNPLA3 genotype in NAFLD patients during the COVID-19 lockdown
2022 F. Cinque, A. Cespiati, R. Lombardi, A. Costantino, G. Maffi, F. Alletto, L. Colavolpe, P. Francione, G. Oberti, E. Fatta, C. Bertelli, G. Sigon, P. Dongiovanni, M. Vecchi, S. Fargion, A.L. Fracanzani
Recreating gut-liver axis during NAFLD onset by using a Caco-2/HepG2 co-culture system
2022 M. Meroni, E. Paolini, M. Longo, R. Piciotti, G. Tria, S. Fargion, A. Ludovica Fracanzani, P. Dongiovanni
$\upalpha$-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study [alpha-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study]
2021 M. Longo, E. Paolini, M. Meroni, L. Duca, I. Motta, A.L. Fracanzani, E. Di Pierro, P. Dongiovanni
Remodeling of mitochondrial plasticity: The key switch from NAFLD/Nash to HCC
2021 M. Longo, E. Paolini, M. Meroni, P. Dongiovanni